ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus

L. Bowman,1 T. Horwedel,1 J. Hagopian,1 B. Bone,2 H. Wijeweera,2 D. Brennan.2

1Barnes-Jewish Hospital, St. Louis
2Washington University School of Medicine, St. Louis.

Meeting: 2015 American Transplant Congress

Abstract number: D123

Keywords: Immunosuppression, Kidney transplantation, Rejection

Session Information

Date: Tuesday, May 5, 2015

Session Name: Poster Session D: Kidney Immunosuppression: Drug Minimization

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Related Abstracts
  • Comparison of Pharmacokinetics and Pharmacogenomics of Once-Daily Extended-Release MeltDose® Tacrolimus Tablets (Envarsus® XR) Vs. Twice-Daily Tacrolimus Capsules in Stable African American Kidney Transplant Patients: A Randomized Cross-Over Study
  • Pharmacokinetics and CYP3A5 Pharmacogenetics for Once- Versus Twice-Daily Tacrolimus from First Dosing Day to 1 Year Post-Transplantation

Purpose: Extended release (ER) tacrolimus (tac) has been available as Advagraf® for many years and as Astagraf XL® in the US since 2013. Immediate release (IR) tac (Prograf®) demonstrates excellent absorption in the a.m. and less robust absorption in the p.m., suggesting it could be prescribed once daily (Qday) in the a.m. A tac PK study showed that a 24-hour trough is a sensitive marker of total body drug exposure in patients receiving daily a.m. dosing (AJT 2004). At our center, we commonly switch patients to Qday dosing of tac.

Methods: We performed a retrospective study of adult renal recipients transplanted 1/1/1999-1/1/2013. Patients switched from twice daily (BID) to Qday IR tac were compared to patients that remained on BID tac. The primary outcome was the incidence of acute rejection (AR). Secondary outcomes included death and graft loss. In patients converted to Qday tac, difference in serum creatinine (SCr), blood pressure (BP), glucose glucose (BG), and tac neurotoxicity pre- and post-conversion were also analyzed.

Results: 1830 patients on BID and 119 patients on Qday IR tac were compared. Median time to switch was 8 (0.25-123) months post-transplant. Major reasons for switch were HLA matching (45.4%) and tac toxicity (42.9%). 5.1% in the BID group and 3.4% in the Qday group experienced AR (p=0.40). Graft loss (16.2% BID vs. 15.1% Qday, p=0.75) and death (9.4% BID vs. 8.4% Qday, p=0.72) were similar. In the 119 patients on Qday tac, the median total daily dose 1 month prior to switch was 3.7mg and 1.8mg at 12 months post-switch (p<0.001). Median tac troughs were 4.3ng/mL at 1 month prior, and 3ng/mL at 12 months post-switch (p=0.134). The median SCr improved by 12 months post-switch (1.5 vs. 1.2mg/dL; p=0.134). BP and BG control was similar pre- vs. post-conversion. Neurotoxicity (tremors or insomnia) was present in 30 patients pre-switch and symptoms improved in 90% post-switch. 80.7% remained on Qday tac at a median of 3.7 (0.1-12.7) years post-switch. 35% of those no longer on Qday tac were withdrawn from tac completely due to a 2 haplotype matched kidney transplant.

Conclusions: Qday dosing of IR tac was not associated with an increase in AR. Post-conversion, there was a non-significant decrease in SCr, and improvement in tac-associated neurotoxicity. We believe that generic IR tac is a less costly alternative to the ER formulations without compromising efficacy.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Bowman L, Horwedel T, Hagopian J, Bone B, Wijeweera H, Brennan D. Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/once-daily-dosing-is-as-effective-as-twice-daily-dosing-of-immediate-release-tacrolimus/. Accessed January 20, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Safety of Statin Therapy After Liver Transplantation.
  • Simultaneous Heart and Kidney Transplant vs Heart Transplant: Single Center Review of Candidate Selection and List Management.
  • Safety and Effectiveness of Valganciclovir for Cytomegalovirus Prophylaxis in Solid Organ Transplant Patients on Hemodialysis
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Safety of Statin Therapy After Liver Transplantation.
  • Safety and Effectiveness of Valganciclovir for Cytomegalovirus Prophylaxis in Solid Organ Transplant Patients on Hemodialysis

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.